Use of genomic test does not increase active surveillance adoption in African-American men
The genomic assay did not increase use of active surveillance in a predominantly African-American population of men with favorable-risk prostate cancer.
The genomic assay did not increase use of active surveillance in a predominantly African-American population of men with favorable-risk prostate cancer.
There were no adverse events, such as penile bruising, swelling, edema, allergy, or penile fracture, observed in patients treated with shockwave therapy plus platelet rich…
“[The] NURE-Combo trial provided insights into the potential value of expanding chemotherapy combinations with immune checkpoint [inhibitors] in muscle-invasive disease,” said Chiara Mercinelli, MD.
Angela B. Smith, MD, MS, highlights key takeaways from the session, “Time Efficiency and Productivity Hacks for the Busy Urologist,” which was presented at the…
“BCG worked well enough that we could give it to patients and it worked pretty well. But having the shortage, I think, has ultimately led…
The addition of 18F-DCFPYL PSMA-PET imaging to multi-parametric MRI was associated with an improvement in the detection of clinically significant prostate cancer in men on…
More patients with nonmetastatic castration-sensitive prostate cancer reached an undetectable PSA level if they received enzalutamide, as a single agent or combined with leuprolide, vs…
“We can all learn and collaborate from each other, that way we can continue to provide really great care for our patients,” says Mary W.…
Treatment with the intravesical gemcitabine delivery system TAR-200 led to complete responses in over 80% of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer, according to…
Extended lymph node dissection during radical cystectomy offered no additional overall survival or disease-free survival benefit vs standard lymph node dissection.
Treatment with apalutamide and androgen deprivation therapy led to a 2-year biochemical recurrence-free survival rate of 100% in patients with high-risk, post-prostatectomy prostate cancer.